Another small sample retrospective study19 revealed that HER2 overexpression DCIS patients were more likely to experience local recurrence (HR, 1.98; 95% CI, 1.11–3.53; p = 0.02). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.